Novo Nordisk Collaborates with University of Oxford
Novo Nordisk entered a research collaboration with the University of Oxford focused on Type 2 diabetes.
On Jan. 30, 2017 Novo Nordisk announced that it is entering a research collaboration with the University of Oxford focused on Type 2 diabetes. As part of the collaboration, Novo Nordisk will be investing in a new research center on the premises of the University of Oxford. Novo Nordisk and University of Oxford have collaborated since 2013 through the International Postdoctoral Fellowship Programme. According to Novo Nordisk, the fellowship program was extended in 2015 and will include up to 32 fellows.
The new research center at Oxford will employ up to 100 Novo Nordisk researchers. The company will invest 1 billion Danish kroner over a period of ten years in the project. The center will focus on early-stage research for the treatment of Type 2 diabetes and complications related to the disease. James D. Johnson, PhD, professor in the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia, will lead the new research center.
Source: Novo Nordisk
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
